Multiple malignancies, including hepatocellular carcinoma, chronic myelogenous leukemia, glioblastoma, and melanoma have aberrant ADAR activity and editing dysregulation (Wang et al., 2017b). This evidence concerns the gene ADAR and chronic myelogenous leukemia, BCR-ABL1 positive.